Value
4.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 5.0 |
| Fwd P/E | 1.0 |
| PEG | 7.6 |
| Analyst target | 3.0 |
- ▸Forward P/E: 195.0x
- ▸PEG: 0.90
TXG · Why this verdict
Why 10x Genomics (TXG) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite reporting GAAP losses, the company generates 19% free cash flow margins and 3% FCF yield, indicating that the genomics platform business has reached a point where operations generate meaningful cash even as accounting expenses for stock compensation and amortization depress reported earnings. Quality breakdown | Free cash flow margin expands to at least 25% over the next 12 months as the revenue base grows and operating leverage improves. | →Stable |
| CounterA Rule of 40 score of only 17 is well below the 40 threshold, indicating that the combined growth and profitability profile is not yet compelling enough to justify a premium valuation. | ||
The company has beaten analyst estimates in all four of the last four quarters with an average positive surprise of 316%, including a 702% beat in the most recent quarter, demonstrating that the business is dramatically outperforming the conservative expectations embedded in analyst models. Earnings | The earnings beat streak extends to at least 6 consecutive quarters and the average positive surprise remains above 100%. | →Stable |
| CounterExtreme earnings beat rates of 316% average are almost certainly driven by analysts modeling worse-than-realized results; as estimates catch up to reality, the beat rate will compress sharply. | ||
At $32.22, the stock is 30.4% above analyst consensus price targets, producing deeply negative asymmetry where the stock would need to fall 30% just to reach the analyst-implied fair value, while the stop loss at $29.96 provides only 7% downside protection. Warnings | Analyst price targets are revised upward to at least $38, restoring a positive reward-to-risk ratio above 1.5 at the current price. | →Stable |
| CounterIf analysts are systematically too low by the magnitude implied by 316% average earnings beats, price targets may be revised dramatically higher on the next report. | ||
A 19% short interest combined with a put/call ratio of 2.60 and implied volatility of 174% indicates strong bearish conviction and extreme cost of hedging, reflecting institutional uncertainty about whether the recent earnings turnaround is sustainable. Risk breakdown | Short interest falls below 10% within the next 12 months as the earnings beat streak reassures skeptics. | →Stable |
| Counter19% short interest in a company with declining revenue and a 30% premium to analyst targets is well-founded and may not unwind quickly even with continued earnings beats. | ||
Despite reporting GAAP losses, the company generates 19% free cash flow margins and 3% FCF yield, indicating that the genomics platform business has reached a point where operations generate meaningful cash even as accounting expenses for stock compensation and amortization depress reported earnings.
→StableQuality breakdown
- Expectation
- Free cash flow margin expands to at least 25% over the next 12 months as the revenue base grows and operating leverage improves.
CounterA Rule of 40 score of only 17 is well below the 40 threshold, indicating that the combined growth and profitability profile is not yet compelling enough to justify a premium valuation.
The company has beaten analyst estimates in all four of the last four quarters with an average positive surprise of 316%, including a 702% beat in the most recent quarter, demonstrating that the business is dramatically outperforming the conservative expectations embedded in analyst models.
→StableEarnings
- Expectation
- The earnings beat streak extends to at least 6 consecutive quarters and the average positive surprise remains above 100%.
CounterExtreme earnings beat rates of 316% average are almost certainly driven by analysts modeling worse-than-realized results; as estimates catch up to reality, the beat rate will compress sharply.
At $32.22, the stock is 30.4% above analyst consensus price targets, producing deeply negative asymmetry where the stock would need to fall 30% just to reach the analyst-implied fair value, while the stop loss at $29.96 provides only 7% downside protection.
→StableWarnings
- Expectation
- Analyst price targets are revised upward to at least $38, restoring a positive reward-to-risk ratio above 1.5 at the current price.
CounterIf analysts are systematically too low by the magnitude implied by 316% average earnings beats, price targets may be revised dramatically higher on the next report.
A 19% short interest combined with a put/call ratio of 2.60 and implied volatility of 174% indicates strong bearish conviction and extreme cost of hedging, reflecting institutional uncertainty about whether the recent earnings turnaround is sustainable.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% within the next 12 months as the earnings beat streak reassures skeptics.
Counter19% short interest in a company with declining revenue and a 30% premium to analyst targets is well-founded and may not unwind quickly even with continued earnings beats.
TrendMatrix Research · core thesis
Engine thesis — one sentence
10x Genomics has delivered four consecutive earnings beats with an average positive surprise exceeding 316% and generates 19% free cash flow margins despite GAAP losses, but the stock has exceeded analyst targets by 30% and carries 19% short interest with a put/call ratio of 2.60 and declining revenue.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 9.9 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.1 |
| FCF quality | 6.9 |
| Moat | 4.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 5.6 |
- ▸FCF-positive despite GAAP loss (FCF margin 19%, FCF yield 2.5%)
- ▸No competitive moat
- ▸Rule of 40: 17 (fail)
Growth
6.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 1.9 |
| EPS growth | 10.0 |
- ▸Declining revenue: -3%
Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 72)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.0 |
| Analyst rating | 7.2 |
| Price target | 1.8 |
- ▸LLM news sentiment: +0.40 (n=1)
- ▸Below analyst target
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $2,517,527 (0.051% of mkt cap)
Peer rank
1.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.7 |
| quality rank | 3.6 |
| growth rank | 0.4 |
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 1.3 |
| 52w position | 9.2 |
Risk (lower is worse)
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.9 |
| days to cover | 3.4 |
| volatility | 0.0 |
| put call | 7.1 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 3.2 |
| debt equity | 0.0 |
- ▸High short interest justified: 26%
- ▸High IV: 96%
- ▸Above max pain $18
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.7>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.40
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-2.3=NEGATIVE
Warning (0)
none
Reward-to-Risk
-2.30
Upside
-34.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 2.04>1.3, MCap $5.0B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Catalyst at 7.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-2.3=NEGATIVE.
The strongest dimensions are Catalyst at 7.0, Momentum at 6.7, and Growth at 6.0; the weakest are Peer rank at 1.4, Risk (lower is worse) at 2.2, and Quality at 3.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -2.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Massive Earnings Beat Streak
Trip ifEPS surprise falls below 50% in at least 3 of the next 4 quarters, signaling mean reversion in the beat rate.
- P2Target Exceeded Sharply
Trip ifStock price drops below $28, more than 13% below the current $32.22, on analyst target downgrades.
- P3Fcf Positive Amid Gaap Loss
Trip ifFree cash flow margin falls below 10% for at least 2 consecutive quarters.
- P4Short Interest Put Call Risk
Trip ifShort interest rises above 25% or put/call ratio rises above 4.0 within the next 6 months.